Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention

NACompletedINTERVENTIONAL
Enrollment

335

Participants

Timeline

Start Date

April 13, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

October 10, 2022

Conditions
Migraine
Interventions
DEVICE

Nerivio active device

Nerivio neurostimulator of conditional pain modulation (CPM)

DEVICE

Nerivio sham device

Nerivio neurostimulator with an electrical output not intended for neurostimulation

Trial Locations (16)

14226

DENT Neurosciences Research Center, Amherst

26506

West Virginia University Medicine, Morgantown

29203

Prevention & Strengthening Solutions, Inc., Columbia

33157

Beautiful Minds Clinical Research Center, Cutler Bay

33472

RecioMed Clinical Research, Boynton Beach

39157

Headache Neurology Research Institute, Ridgeland

42001

Four Rivers Clinical Research, Paducah

47713

Deaconess Clinic, Evansville

60657

Chicago Headache Center and Research Institute, Chicago

63303

StudyMetrix Research, City of Saint Peters

65810

ClinVest Research, Springfield

85013

Evolve Clinical Research, Phoenix

92011

The Neurology Center of Southern California, Carlsbad

92663

Newport Beach Clinical Research Associates, Newport Beach

06107

Hartford Headache Center, Hartford

08755

Ocean medical research, Toms River

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Theranica

INDUSTRY

NCT04828707 - Assessment of Safety and Efficacy of Nerivio for the Migraine Prevention | Biotech Hunter | Biotech Hunter